Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | oxidoreductase-like protein | 0.0085 | 0 | 0.5 |
Schistosoma mansoni | Replicative DNA helicase | 0.1921 | 0.336 | 1 |
Mycobacterium tuberculosis | Probable replicative DNA helicase DnaB | 0.1921 | 0.336 | 1 |
Treponema pallidum | replicative DNA helicase (dnaB) | 0.1921 | 0.336 | 0.5 |
Chlamydia trachomatis | replicative DNA helicase | 0.1921 | 0.336 | 1 |
Trichomonas vaginalis | hypothetical protein | 0.1142 | 0.1935 | 0.5 |
Loa Loa (eye worm) | twinkle helicase | 0.0549 | 0.0849 | 1 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.1142 | 0.1935 | 0.5758 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.1142 | 0.1935 | 1 |
Leishmania major | oxidoreductase-like protein | 0.0085 | 0 | 0.5 |
Brugia malayi | Apoptosis regulator proteins, Bcl-2 family protein | 0.0518 | 0.0793 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | replicative DNA helicase | 0.1921 | 0.336 | 1 |
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0085 | 0 | 0.5 |
Mycobacterium ulcerans | replicative DNA helicase DnaB | 0.1921 | 0.336 | 1 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.1142 | 0.1935 | 0.5758 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.1142 | 0.1935 | 0.5 |
Leishmania major | pteridine reductase 1 | 0.0085 | 0 | 0.5 |
Echinococcus multilocularis | EGFP:Bcl2 fusion protein | 0.555 | 1 | 1 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.1142 | 0.1935 | 1 |
Mycobacterium leprae | PROBABLE REPLICATIVE DNA HELICASE DNAB replicative DNA helicase | 0.1921 | 0.336 | 1 |
Onchocerca volvulus | 0.0085 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.